Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schwetz, V; Trummer, C; Pandis, M; Grübler, MR; Verheyen, N; Gaksch, M; Zittermann, A; März, W; Aberer, F; Lang, A; Treiber, G; Friedl, C; Obermayer-Pietsch, B; Pieber, TR; Tomaschitz, A; Pilz, S.
Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial.
Nutrients. 2017; 9(5):
Doi: 10.3390/nu9050432
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Theiler-Schwetz Verena
- Trummer Christian
- Co-Autor*innen der Med Uni Graz
- Aberer Felix
- Grübler Martin
- Keppel Martin
- Lackner Claudia
- März Winfried
- Obermayer-Pietsch Barbara
- Pandis Marlene
- Pieber Thomas
- Pilz Stefan
- Tomaschitz Andreas
- Treiber Gerlies
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011-2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels <75 nmol/L were randomized to 2800 IU of vitamin D daily or placebo for eight weeks. One hundred ninety-seven participants (60.2 ± 11.1 years; 47% women) were included in this analysis. Vitamin D had no significant effect on bALP (mean treatment effect (MTE) 0.013, 95% CI -0.029 to 0.056 µg/L; p = 0.533), CTX (MTE 0.024, 95% CI -0.163 to 0.210 ng/mL, p = 0.802), OC (MTE 0.020, 95% CI -0.062 to 0.103 ng/mL, p = 0.626), or P1NP (MTE -0.021, 95% CI -0.099 to 0.057 ng/mL, p = 0.597). Analyzing patients with 25(OH)D levels <50 nmol/L separately (n = 74) left results largely unchanged. In hypertensive patients with low 25(OH)D levels, we observed no significant effect of vitamin D supplementation for eight weeks on BTMs.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Alkaline Phosphatase - genetics, metabolism
- Biomarkers - blood
- Bone Remodeling - drug effects
- Double-Blind Method - administration & dosage
- Female - administration & dosage
- Gene Expression Regulation - drug effects
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Osteocalcin - genetics, metabolism
- Peptide Fragments - genetics, metabolism
- Procollagen - genetics, metabolism
- Vitamin D - administration & dosage, analogs & derivatives, blood, pharmacology
- Find related publications in this database (Keywords)
- vitamin D supplementation
- bone turnover markers
- osteocalcin
- procollagen type 1 N-terminal propeptide
- crosslaps
- bone-specific alkaline phosphatase